vs
Omega Flex, Inc.（OFLX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Omega Flex, Inc.的1.2倍（$30.3M vs $25.2M），Omega Flex, Inc.净利率更高（13.5% vs -221.3%，领先234.9%），REGENXBIO Inc.同比增速更快（43.0% vs -6.5%），Omega Flex, Inc.自由现金流更多（$7.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.0%）
Smart Omega Esports是菲律宾的知名职业电竞战队，前身为PLDT–Smart Omega，战队以加盟制运营，目前参与菲律宾顶级电竞联赛《The Nationals》以及菲律宾移动 legends 职业联赛（MPL Philippines）的赛事。该战队由电竞俱乐部Sterling Global Dragons与菲律宾电信企业PLDT及其移动部门Smart Communications合资成立。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OFLX vs RGNX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.2M | $30.3M |
| 净利润 | $3.4M | $-67.1M |
| 毛利率 | 59.2% | — |
| 营业利润率 | 15.8% | -190.0% |
| 净利率 | 13.5% | -221.3% |
| 营收同比 | -6.5% | 43.0% |
| 净利润同比 | -27.1% | -31.2% |
| 每股收益（稀释后） | $0.34 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $25.2M | $30.3M | ||
| Q3 25 | $24.2M | $29.7M | ||
| Q2 25 | $25.5M | $21.4M | ||
| Q1 25 | $23.3M | $89.0M | ||
| Q4 24 | $27.0M | $21.2M | ||
| Q3 24 | $24.9M | $24.2M | ||
| Q2 24 | $24.6M | $22.3M | ||
| Q1 24 | $25.2M | $15.6M |
| Q4 25 | $3.4M | $-67.1M | ||
| Q3 25 | $3.7M | $-61.9M | ||
| Q2 25 | $4.2M | $-70.9M | ||
| Q1 25 | $3.6M | $6.1M | ||
| Q4 24 | $4.7M | $-51.2M | ||
| Q3 24 | $4.6M | $-59.6M | ||
| Q2 24 | $4.5M | $-53.0M | ||
| Q1 24 | $4.2M | $-63.3M |
| Q4 25 | 59.2% | — | ||
| Q3 25 | 60.2% | — | ||
| Q2 25 | 60.4% | — | ||
| Q1 25 | 60.3% | — | ||
| Q4 24 | 61.5% | 70.2% | ||
| Q3 24 | 61.7% | 48.8% | ||
| Q2 24 | 61.8% | 52.5% | ||
| Q1 24 | 59.9% | 72.6% |
| Q4 25 | 15.8% | -190.0% | ||
| Q3 25 | 17.3% | -176.3% | ||
| Q2 25 | 18.5% | -296.3% | ||
| Q1 25 | 17.4% | 13.6% | ||
| Q4 24 | 21.4% | -242.1% | ||
| Q3 24 | 22.0% | -256.6% | ||
| Q2 24 | 21.5% | -251.3% | ||
| Q1 24 | 20.1% | -408.8% |
| Q4 25 | 13.5% | -221.3% | ||
| Q3 25 | 15.2% | -208.3% | ||
| Q2 25 | 16.3% | -331.8% | ||
| Q1 25 | 15.3% | 6.8% | ||
| Q4 24 | 17.4% | -241.3% | ||
| Q3 24 | 18.6% | -246.3% | ||
| Q2 24 | 18.3% | -237.7% | ||
| Q1 24 | 16.7% | -405.4% |
| Q4 25 | $0.34 | $-1.30 | ||
| Q3 25 | $0.37 | $-1.20 | ||
| Q2 25 | $0.41 | $-1.38 | ||
| Q1 25 | $0.35 | $0.12 | ||
| Q4 24 | $0.45 | $-0.99 | ||
| Q3 24 | $0.46 | $-1.17 | ||
| Q2 24 | $0.45 | $-1.05 | ||
| Q1 24 | $0.42 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $84.2M | $102.7M |
| 总资产 | $105.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $53.2M | $230.1M | ||
| Q3 25 | $49.4M | $274.2M | ||
| Q2 25 | $50.7M | $323.3M | ||
| Q1 25 | $49.2M | $267.9M | ||
| Q4 24 | $51.7M | $234.7M | ||
| Q3 24 | $45.9M | $255.5M | ||
| Q2 24 | $45.7M | $290.4M | ||
| Q1 24 | $45.3M | $338.7M |
| Q4 25 | $84.2M | $102.7M | ||
| Q3 25 | $84.2M | $161.5M | ||
| Q2 25 | $84.0M | $213.7M | ||
| Q1 25 | $83.3M | $274.2M | ||
| Q4 24 | $83.1M | $259.7M | ||
| Q3 24 | $82.0M | $301.4M | ||
| Q2 24 | $80.6M | $348.3M | ||
| Q1 24 | $79.6M | $390.7M |
| Q4 25 | $105.0M | $453.0M | ||
| Q3 25 | $103.8M | $525.2M | ||
| Q2 25 | $102.8M | $581.0M | ||
| Q1 25 | $102.8M | $490.9M | ||
| Q4 24 | $105.9M | $466.0M | ||
| Q3 24 | $102.9M | $519.1M | ||
| Q2 24 | $99.6M | $569.4M | ||
| Q1 24 | $99.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $7.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 28.9% | -174.0% |
| 资本支出强度资本支出/营收 | 0.8% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.20× | — |
| 过去12个月自由现金流最近4个季度 | $15.4M | $-126.4M |
8季度趋势，按日历期对齐
| Q4 25 | $7.5M | $-52.3M | ||
| Q3 25 | $2.7M | $-56.0M | ||
| Q2 25 | $5.5M | $-49.3M | ||
| Q1 25 | $1.6M | $33.6M | ||
| Q4 24 | $9.8M | $-31.6M | ||
| Q3 24 | $4.0M | $-40.5M | ||
| Q2 24 | $4.4M | $-45.5M | ||
| Q1 24 | $2.7M | $-55.5M |
| Q4 25 | $7.3M | $-52.8M | ||
| Q3 25 | $2.0M | $-56.5M | ||
| Q2 25 | $5.0M | $-49.7M | ||
| Q1 25 | $1.0M | $32.6M | ||
| Q4 24 | $9.2M | $-32.7M | ||
| Q3 24 | $3.6M | $-40.9M | ||
| Q2 24 | $3.8M | $-46.0M | ||
| Q1 24 | $2.2M | $-56.0M |
| Q4 25 | 28.9% | -174.0% | ||
| Q3 25 | 8.4% | -189.9% | ||
| Q2 25 | 19.6% | -232.8% | ||
| Q1 25 | 4.3% | 36.6% | ||
| Q4 24 | 34.1% | -154.2% | ||
| Q3 24 | 14.7% | -168.9% | ||
| Q2 24 | 15.3% | -206.2% | ||
| Q1 24 | 8.9% | -358.5% |
| Q4 25 | 0.8% | 1.7% | ||
| Q3 25 | 2.5% | 1.7% | ||
| Q2 25 | 1.7% | 1.8% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 2.1% | 5.1% | ||
| Q3 24 | 1.4% | 1.3% | ||
| Q2 24 | 2.6% | 2.1% | ||
| Q1 24 | 1.8% | 3.6% |
| Q4 25 | 2.20× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 0.44× | 5.53× | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 0.86× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFLX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
